Abstract
We measured serum dihydroxyvitamin D (1, 25(OH)2D) levels by non-HPLC radioreceptor assay and examined its usefulness in 48 hemodialysis (HD) patients. A good positive correlation (r=0.72, p<0.01) was demonstrated between serum levels of 1, 25(OH)2D measured by non-HPLC and by HPLC. Serum levels of 1, 25(OH)2D in non-dialysis chronic renal failure patients, in HD patients not receiving vitamin D, in HD patients receiving vitamin D (1, 25(OH)2D in one patient and 1α(OH)D in 29 patients), and in HD patients treated with oral 1, 25(OH)2D pulse therapy were lower than in the controls. Serum 1, 25(OH)2D levels in HD patients treated with 0.25μg of 1α(OH)D were no different from those in the controls, whereas in HD patients treated with 0.5μg of 1α(OH)D they were higher than in HD patients not receiving vitamin D. Serum 1, 25(OH)2D was not correlated with intact-PTH, serum phosphorus, or alkaline phosphatase. A significant positive correlation was observed between serum 1, 25(OH)2D and serum calcium (r=0.44, p<0.01).
In conclusion, determination of serum 1, 25(OH)2D by non-HPLC radioreceptor assay is useful in the management of renal osteodystrophy in HD patients.
